Market Overview
[Pages:1]Q2-2017 CRO Update
Market Overview
The mergers and acquisitions marketplace was robust in the second quarter of 2017. Several of the industry's largest players were involved in transactions that are sure to alter the future of the CRO and outsourced research landscape. The merger of INC Research and InVentiv Health has created one of the largest clinical research providers in the world. Parexel, one of the industry's largest contributors, has been taken private by Pamplona Capital Management. The continued interest from the private equity community, demonstrated by Pamplona Capital, Audax Group, Auctus Capital Partners, and The Carlyle Group all making investments into the space, will continue to fuel an active transaction marketplace for the remainder of 2017.
SELECT TRANSACTIONS:
Date Acquirer
June 2017
Pamplona Capital
Management
June 2017
Audax Group
Target Parexel (NASDAQ: PRXL)
Altasciences Company
Description Pamplona Capital Management will take publicly-traded Parexel International Corp. private. Pamplona's $5 billion offer values Parexel at a 28% premium. The Massachusetts-based company, with over 19,000 employees worldwide, offers expertise in Phase I-IV clinical research to biopharmaceutical and medical device companies.
Audax Group announced the acquisition of Quebec-based Altasciences Company, a leading early-phase contract research organization. Their service offerings include clinical trials, data management, biostatistics, medical writing, and bioanalysis. Audax acquired Altasciences from Kilmer Capital Partners. Terms of the transaction were not disclosed.
June 2017
Tentamus (Auctus Capital
Partners)
Symbiotic Research
Symbiotic Research (SR) has been acquired by Auctus Capital Partners'-backed Tentamus Group, a global product testing and safety group with more than 30 locations worldwide. SR, an operator of a life sciences contract research organization located in New Jersey, helps pharmaceutical and biotechnology companies with product development and registration needs. Terms of the transaction were not disclosed.
Albany Molecular Research (AMRI), a global contract research organization working
The Carlyle Albany Molecular within the life sciences industry for more than 25 years, has agreed to be acquired by
June
Group
Research The Carlyle Group. The offer of $21.75 per share represents a 42% premium to the 60-
2017 (NASDAQ: (NASDAQ: day weighted average closing price. AMRI's key business segments are discovery and
CG)
AMRI)
development services, active pharmaceutical ingredients, drug products, and fine
chemicals. The company operates in North America, Europe, and Asia.
Thermo Fisher May Scientific 2017 (NYSE:
TMO)
Patheon NV (NYSE: PTHN)
Contract development and manufacturing organization Pantheon will be acquired by Thermo Fisher Scientific for $5.2 billion. Thermo Fisher's offer of $45 per share represents a 35% premium. Headquartered in North Carolina, the company makes ingredients for small molecule drugs and helps drug makers through clinical trials. The acquisition is expected to close by the end of the year.
INC Research, a global Phase I-IV contract research organization, and inVentiv Health,
May 2017
INC Research
a privately-held CRO and Contract Commercial Organization, announced a definitive
(NASDAQ: InVentiv Health merger agreement. The deal values inVentiv at $4.6 billion and the combined entity at
INCR)
$7.4 billion. The merged entity would be a top three CRO globally and the leading CCO
provider with over 22,000 employees in more than 60 countries.
Australian contract research organization George Clinical acquired Vector Oncology's
May 2017
George Clinical
Vector Oncology (CRO Division)
Pharma Service (CRO) Division. Vector Oncology, with headquarters in Memphis, TN, is a leader in oncology research and data analytics. The acquisition not only strengthens George Clinical's operations in Asia-Pacific, but also expands the company's expertise
to the United States. Terms of the transaction were not disclosed.
Provident Healthcare Partners
Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident He althcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- west point pa vaccine sales representative inventiv
- clinical research acro
- 199 2013 from sdtm to adam sas technical support
- the europe cdisc coordinating committee e3c has planned
- executive summary the avoca group
- sneha sarmukadam inventiv health clinical pune india
- cpsa usa 2017 meeting program
- market overview
- redefining early phase clinical services
- contract research organizations chiltern
Related searches
- overview of starbucks
- starbucks overview of the company
- overview of photosynthesis
- overview of photosynthesis quizlet
- activity overview of photosynthesis
- brief overview of starbucks
- overview of photosynthesis review worksheet
- overview of philosophers beliefs
- overview of photosynthesis 4.2 answers
- overview of photosynthesis worksheet
- brief overview of a meeting
- section 4.2 overview of photosynthesis